We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Bone Hormone Levels Predict Heart Failure Deaths

By LabMedica International staff writers
Posted on 22 Sep 2010
Circulating levels of a bone hormone are predictive of death and hospitalization for heart failure after acute coronary syndrome. More...


The level of osteoprotegerin (OPG), a member of the tumor necrosis factor receptor superfamily, can be measured using an enzyme-linked immunosorbent assay (ELISA) utilizing monoclonal antibodies.

A study OPG levels in the plasma of 1,229 patients with chronic heart failure (CHF) from 51 clinical centers, was carried out at Akershus University Hospital (Lørenskog, Norway). OPG levels were quantified by an in-house time-resolved immunofluorometric assay modified from an ELISA using commercially available monoclonal antibodies (R&D Systems; Abingdon, UK). The limit of detection for OPG was 15 ng/L.

During a median follow-up time of 3.9 years, 332 patients died and 791 patients died or were hospitalized because of cardiovascular causes. The median value of OPG was 1,509 ng/L (interquartile range: 1,102-2,185 ng/L). Circulating OPG levels were associated with a number of conventional risk markers. Patients with higher OPG levels were more likely to be older, to be female, to have more severe heart failure as evaluated by higher functional evaluation, and to have heart failure of ischemic etiology.

The main findings of this study of patients with CHF are that circulating concentrations of OPG are strongly and independently associated with all-cause mortality as well as with the incidence of the combined end point of mortality or cardio-vascular events. However, reclassification analyses suggest that the statistically significant association is unlikely to improve risk stratification of heart failure patients in a clinically meaningful way. The results showed that patients with the highest tertile of OPG were twice as likely to die during follow-up as the patients with the lowest tertile levels of OPG were.

Torbjørn Omland, M.D. Ph.D., the lead author of study, said, "The finding is interesting not only because it suggests that there is a link between bone metabolism and heart disease, but because it might help to identify heart failure patients who are at greatest risk. As medical practitioners, we can then target those patients earlier with intensified therapy.” The study was published in August 2010 issue of the American Heart Journal.

Related Links:
Akershus University Hospital
R&D Systems


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.